2-(1-tert-butoxycarbonyl-4-piperidyl)-2-(4-fluorophenyl)acetic acid | 552885-77-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(1-tert-butoxycarbonyl-4-piperidyl)-2-(4-fluorophenyl)acetic acid
• 英文别名: 1-t-Butoxycarbonyl-4-[carboxy-(4-fluorophenyl)methyl]piperidine；2-(4-fluorophenyl)-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]acetic acid
• CAS: 552885-77-5
• 化学式: C₁₈H₂₄FNO₄
• 分子量: 337.391
• InChiKey: GSIWCWPTTARLGU-UHFFFAOYSA-N

物化性质

• 沸点：
  452.1±20.0 °C(Predicted)
• 密度：
  1.208±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(1-tert-butoxycarbonyl-4-piperidyl)-2-(4-fluorophenyl)acetic acid 在 盐酸 、 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成
  参考文献：
  名称：

  Novel piperazines: Potent melanocortin-4 receptor antagonists with anxiolytic-like activity

  摘要：

  In the present study, we found that a novel piperazine compound, 11a, showed a moderate affinity (IC50 = 333 nM) for the MC4 receptor. We developed the new type of piperazine compounds and found that mono-piperazine 11b exhibited a high-affinity (IC50 = 40.3 nM) for the MC4 receptor. We also found that a series of biphenyl analogues exhibited a high-affinity for the receptor, and in particular, compound 11j exhibited the highest affinity for the MC4 receptor with an IC50 value of 14.5 nM. Further-more, some of these compounds, when administered orally, significantly reversed the stress-induced anxiety-like behavior in rats. In this paper, we report the synthesis, structure-activity relationships, and oral activity of the novel mono-piperazines as MC4 receptor antagonists. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.01.019
• 作为产物：
  描述：

  [1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl](4-fluorophenyl)acetic acid 在 氢氧化钯 氢气 作用下， 以 甲醇 为溶剂， 反应 48.0h， 以to give 3.6 g of a crude 1-t-butoxycarbonyl-4-[carboxy-(4-fluorophenyl)methyl]piperidine的产率得到2-(1-tert-butoxycarbonyl-4-piperidyl)-2-(4-fluorophenyl)acetic acid
  参考文献：
  名称：

  Remedial agent for anxiety neurosis or depression and piperazine derivative

  摘要：

  提供了一种治疗焦虑神经症或抑郁症的制剂，其包含MC4受体拮抗剂作为有效成分；以及由式子[1]表示的哌嗪衍生物：1[其中Ar1为苯基，取代苯基，萘基或取代萘基；Ar2为萘基，取代萘基，喹啉基，由式子2表示的基团（其中R4为氢原子或卤素原子；X-Y为CH-NH，CH-O，CH-S或N-O），或由式子3表示的基团（其中R5为氢原子，羟基或C1-10烷氧基）；R1为氢原子，C1-10烷基，C3-8环烷基，C3-10烯基，苯基，1-氰基乙基，嘧啶-2-基基团或酰胺基团；R2和R3相同或不同，均为氢原子或C1-10烷基；A-B为N-CH2，CH-CH2，C(OH)-CH2或C=CH；T1为单键，-N(R6)-（其中R6为氢原子或C1-10烷基），-O-，-CH=CH-或-C(=O)-；n为1至10的整数，当T1为单键，-CH=CH-或-C(=O)-时，n为2至10的整数，当T1为-N(R6)-或-O-时，则n为1至10的整数]，或其药学上可接受的盐。

  公开号：

  US20030186992A1

文献信息

• Remedial agent for anxiety neurosis or depression and piperazine derivative
  申请人：——

  公开号：US20030186992A1

  公开（公告）日：2003-10-02

  There are provided a therapeutic preparation for anxiety neurosis or depression which comprises a MC 4 receptor antagonist as an effective ingredient; and a piperazine derivative represented by Formula [1]: 1 [wherein Ar 1 is a phenyl group, a substituted phenyl group, a naphthyl group or a substituted naphthyl group; Ar 2 is a naphthyl group, a substituted naphthyl group, a quinolyl group, a group represented by the formula: 2 (wherein R 4 is a hydrogen atom or a halogen atom; and X—Y is CH—NH, CH—O, CH—S or N—O) or a group represented by the formula: 3 (wherein R 5 is a hydrogen atom, a hydroxyl group or a C 1-10 alkoxy group); R 1 is a hydrogen atom, a C 1-10 alkyl group, a C 3-8 cycloalkyl group, a C 3-10 alkenyl group, a phenyl group, a 1-cyanoethyl group, a pyrimidin-2-yl group or an amidyl group; R 2 and R 3 are the same or different, and are each a hydrogen atom or a C 1-10 alkyl group; A-B is N—CH 2 , CH—CH 2 , C(OH)—CH 2 or C═CH; T 1 is a single bond, —N(R 6 )— (wherein R 6 is a hydrogen atom or a C 1-10 alkyl group), —O—, —CH═CH— or —C(═O)—; n is an integer of from 1 to 10 and when T 1 is a single bond, —CH═CH— or —C(═O)—, n is an integer of from 2 to 10 when T 1 is —N(R 6 )— or —O—], or a pharmaceutically acceptable salt thereof.

  提供了一种治疗焦虑神经症或抑郁症的药物制剂，包括MC4受体拮抗剂作为有效成分；以及由式[1]表示的哌嗪衍生物：1[其中Ar1是苯基、取代苯基、萘基或取代萘基；Ar2是萘基、取代萘基、喹啉基、由式2表示的基团（其中R4是氢原子或卤原子；且X—Y是CH—NH、CH—O、CH—S或N—O）或由式3表示的基团（其中R5是氢原子、羟基或C1-10烷氧基）；R1是氢原子、C1-10烷基、C3-8环烷基、C3-10烯基、苯基、1-氰乙基基团、嘧啶-2-基基团或酰基基团；R2和R3相同或不同，各自是氢原子或C1-10烷基；A-B是N—CH2、CH—CH2、C(OH)—CH2或C；T1是单键、—N(R6)—（其中R6是氢原子或C1-10烷基）、—O—、—CHCH—或—C(O)—；n是1到10的整数，当T1是单键、—CHCH—或—C(O)—时，n是2到10的整数，当T1是—N(R6)—或—O—时，或其在药学上可接受的盐。
• Piperazine derivative
  申请人：Nakazato Atsuro

  公开号：US20060084657A1

  公开（公告）日：2006-04-20

  A piperazine derivative represented by the formula (1): wherein n is an integer of 1 to 8; R 1 represents hydrogen or C 1-10 alkyl; A represents CH or nitrogen; Ar 1 represents phenyl or substituted phenyl; and Y represents a group represented by the formula Y 1 -Y 2 -Ar 2 or Y 3 -Y 4 (Ar 5 )-Ar 6 or a pharmaceutically acceptable salt of the derivative. The novel piperazine derivative has MC4 receptor antagonistic activity.

  一种由式（1）表示的哌嗪衍生物： 其中n为1至8的整数；R1表示氢或C1-10烷基；A表示CH或氮；Ar1表示苯基或取代苯基；Y表示由式Y1-Y2-Ar2或Y3-Y4（Ar5）-Ar6表示的基团，或该衍生物的药学上可接受的盐。该新型哌嗪衍生物具有MC4受体拮抗活性。
• [EN] HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2022223750A1

  公开（公告）日：2022-10-27

  The invention provides new heterocyclic compounds having the general formula (I), wherein A, B, X, and R1to R7are as described herein, compositions including thecompounds, processes of manufacturing the compounds and methods of using the compounds.

  本发明提供了具有通式（I）（其中 A、B、X 和 R1 至 R7 如本文所述）的新杂环化合物、包括该化合物的组合物、制造该化合物的工艺和使用该化合物的方法。
• REMEDIAL AGENT FOR ANXIETY NEUROSIS OR DEPRESSION AND PIPERAZINE DERIVATIVE
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：EP1295608A1

  公开（公告）日：2003-03-26

  There are provided a therapeutic preparation for anxiety neurosis or depression which comprises a MC4 receptor antagonist as an effective ingredient; and a piperazine derivative represented by Formula [1]: [wherein Ar1 is a phenyl group, a substituted phenyl group, a naphthyl group or a substituted naphthyl group; Ar2 is a naphthyl group, a substituted naphthyl group, a quinolyl group, a group represented by the formula: (wherein R4 is a hydrogen atom or a halogen atom; and X-Y is CH-NH, CH-O, CH-S or N-O) or a group represented by the formula: (wherein R5 is a hydrogen atom, a hydroxyl group or a C1-10 alkoxy group); R1 is a hydrogen atom, a C1-10 alkyl group, a C3-8 cycloalkyl group, a C3-10 alkenyl group, a phenyl group, a 1-cyanoethyl group, a pyrimidin-2-yl group or an amidyl group; R2 and R3 are the same or different, and are each a hydrogen atom or a C1-10 alkyl group; A-B is N-CH2, CH-CH2, C(OH)-CH2 or C=CH; T1 is a single bond, -N(R6)- (wherein R6 is a hydrogen atom or a C1-10 alkyl group), -O-, -CH=CH- or -C(=O)-; n is an integer of from 1 to 10 and when T1 is a single bond, -CH=CH- or -C(=O)-, n is an integer of from 2 to 10 when T1 is -N(R6)- or -O-], or a pharmaceutically acceptable salt thereof.

  提供了一种治疗焦虑神经症或抑郁症的制剂，它包括作为有效成分的 MC4 受体拮抗剂；以及由式[1]表示的哌嗪衍生物： 其中Ar1是苯基、取代的苯基、萘基或取代的萘基；Ar2是萘基、取代的萘基、喹啉基、由式[1]代表的基团： (其中 R4 是氢原子或卤素原子；X-Y 是 CH-NH、CH-O、CH-S 或 N-O）或由式表示的基团： (其中 R5 是氢原子、羟基或 C1-10 烷氧基）；R1 是氢原子、C1-10 烷基、C3-8 环烷基、C3-10 烯基、苯基、1-氰乙基、嘧啶-2-基或酰胺基；R2 和 R3 相同或不同，且各自是氢原子或 C1-10 烷基；A-B是N-CH2、CH-CH2、C(OH)-CH2或C＝CH；T1是单键、-N(R6)-（其中R6是氢原子或C1-10烷基）、-O-、-CH＝CH-或-C(＝O)-；n 为 1-10 的整数，当 T1 为单键时，为-CH=CH-或-C(=O)-，当 T1 为-N(R6)-或-O-时，n 为 2-10 的整数]，或其药学上可接受的盐。
• PIPERAZINE DERIVATIVE
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP1468990A1

  公开（公告）日：2004-10-20

  A piperazine derivative represented by the formula (1):    wherein n is an integer of 1 to 8; R1 represents hydrogen or C1-10 alkyl; A represents CH or nitrogen; Ar1 represents phenyl or substituted phenyl; and Y represents a group represented by the formula Y1-Y2-Ar2 or Y3-Y4(Ar5)-Ar6 or a pharmaceutically acceptable salt of the derivative. The novel piperazine derivative has MC4 receptor antagonistic activity.

  一种由式（1）代表的哌嗪衍生物： 其中 n 为 1 至 8 的整数；R1 代表氢或 C1-10 烷基；A 代表 CH 或氮；Ar1 代表苯基或取代苯基；Y 代表由式 Y1-Y2-Ar2 或 Y3-Y4(Ar5)-Ar6 所代表的基团或该衍生物的药学上可接受的盐。新型哌嗪衍生物具有 MC4 受体拮抗活性。